Veliger
Bullish
now
$AVXL lots of discussion this morning on the new trial sites for the RETT EXCELLENCE study, but I'd encourage everyone to focus more on how dramatically this study has changed in terms of primary and secondary endpoints...so many measures added, which I expect will serve to bridge study design with the pending Fragile X study in pediatric patients. You can bet they've already received agency guidance there. Check out the history of changes here, side-by-side comparison: clinicaltrials.gov/ct2/hist...
2
17
17 Likes